Gilead quash­es mi­cro­cap biotech's hope of part­ner­ing on oral Covid-19 drug

Gilead is call­ing it quits on a two-year-old project to de­vel­op an oral for­mu­la­tion of its Covid-19 an­tivi­ral remde­sivir, its biotech coun­ter­parts at Mati­nas Bio­Phar­ma …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER